Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
| dc.contributor.author | Pavel, M | |
| dc.contributor.author | Singh, S | |
| dc.contributor.author | Strosberg, J | |
| dc.contributor.author | Bubuteishvili-Pacaud, L | |
| dc.contributor.author | Degtyarev, E | |
| dc.contributor.author | Neary, M | |
| dc.contributor.author | Carnaghi, C | |
| dc.contributor.author | Tomasek, J | |
| dc.contributor.author | Wolin, E | |
| dc.contributor.author | Raderer, M | |
| dc.contributor.author | Lahner, H | |
| dc.contributor.author | Valle, Juan W | |
| dc.contributor.author | Pommier, R | |
| dc.contributor.author | Van Cutsem, E | |
| dc.contributor.author | Tesselaar, M | |
| dc.contributor.author | Fave, G | |
| dc.contributor.author | Buzzoni, R | |
| dc.contributor.author | Hunger, M | |
| dc.contributor.author | Eriksson, J | |
| dc.contributor.author | Cella, D | |
| dc.contributor.author | Ricci, J | |
| dc.contributor.author | Fazio, N | |
| dc.contributor.author | Kulke, M | |
| dc.contributor.author | Yao, J | |
| dc.date.accessioned | 2017-09-22T15:38:10Z | |
| dc.date.available | 2017-09-22T15:38:10Z | |
| dc.date.issued | 2017-08-21 | |
| dc.identifier.citation | Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. 2017 Lancet Oncol | en |
| dc.identifier.issn | 1474-5488 | |
| dc.identifier.pmid | 28838862 | |
| dc.identifier.doi | 10.1016/S1470-2045(17)30471-0 | |
| dc.identifier.uri | http://hdl.handle.net/10541/620568 | |
| dc.description.abstract | In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint. | |
| dc.language.iso | en | en |
| dc.rights | Archived with thanks to The Lancet. Oncology | en |
| dc.title | Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. | en |
| dc.type | Article | en |
| dc.contributor.department | Department of Hepatology and Gastroenterology, Charite Universitatsmedizin Berlin, Campus Virchow-Klinikum, Berlin, Germany | en |
| dc.identifier.journal | The Lancet Oncology | en |
| html.description.abstract | In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint. |